Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

Jianying Luo, Ping Guo, Kei Matsuda, Nhan Truong, Annie Lee, Carlene Chun, Shi Yuan Cheng, Murray Korc

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulator that acts by binding to high-affinity transmembrane receptors. Although both VEGF and its receptors are overexpressed in human pancreatic ductal adenocarcinoma (PDAC), this malignancy is not generally considered to be highly vascular. It is not known, therefore, whether the abundance of VEGF in PDAC is biologically relevant. To address this issue, we measured the angiogenic effects of pancreatic cancer cell-derived VEGF in an in vitro endothelial cell proliferation assay and characterized the consequences of suppressing VEGF expression on pancreatic tumor growth in an athymic nude mouse model. We found that human pancreatic cancer cell lines secrete large quantities of biologically active VEGF into conditioned medium (CM). Stable transfection of an anti-sense VEGF189 (AS-VEGF189) expression construct into PANC-1 pancreatic cancer cells resulted in decreased VEGF expression and secretion, a decreased capacity of the resultant CM to enhance endothelial cell proliferation and a significant attenuation of tumor cell proliferation in vitro. Furthermore, when injected into athymic nude mice, AS-VEGF189-expressing cells exhibited an 80% decrease in tumor growth compared with control cells. These results support the hypothesis that VEGF promotes pancreatic cancer growth in vivo and suggest that anti-VEGF therapy may be useful in the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalInternational Journal of Cancer
Volume92
Issue number3
DOIs
StatePublished - May 1 2001
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
Nude Mice
Cell Proliferation
Conditioned Culture Medium
Neoplasms
Adenocarcinoma
Endothelial Cells
Growth
Vascular Endothelial Growth Factor Receptor
In Vitro Techniques
Transfection
Blood Vessels
Cell Line

Keywords

  • Angiogensis
  • Anti-sense RNA
  • Pancreatic cancer
  • Tumorigenicity
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. / Luo, Jianying; Guo, Ping; Matsuda, Kei; Truong, Nhan; Lee, Annie; Chun, Carlene; Cheng, Shi Yuan; Korc, Murray.

In: International Journal of Cancer, Vol. 92, No. 3, 01.05.2001, p. 361-369.

Research output: Contribution to journalArticle

Luo, Jianying ; Guo, Ping ; Matsuda, Kei ; Truong, Nhan ; Lee, Annie ; Chun, Carlene ; Cheng, Shi Yuan ; Korc, Murray. / Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. In: International Journal of Cancer. 2001 ; Vol. 92, No. 3. pp. 361-369.
@article{8e4803ac45fe45ae81e46eb6833b4d39,
title = "Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo",
abstract = "Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulator that acts by binding to high-affinity transmembrane receptors. Although both VEGF and its receptors are overexpressed in human pancreatic ductal adenocarcinoma (PDAC), this malignancy is not generally considered to be highly vascular. It is not known, therefore, whether the abundance of VEGF in PDAC is biologically relevant. To address this issue, we measured the angiogenic effects of pancreatic cancer cell-derived VEGF in an in vitro endothelial cell proliferation assay and characterized the consequences of suppressing VEGF expression on pancreatic tumor growth in an athymic nude mouse model. We found that human pancreatic cancer cell lines secrete large quantities of biologically active VEGF into conditioned medium (CM). Stable transfection of an anti-sense VEGF189 (AS-VEGF189) expression construct into PANC-1 pancreatic cancer cells resulted in decreased VEGF expression and secretion, a decreased capacity of the resultant CM to enhance endothelial cell proliferation and a significant attenuation of tumor cell proliferation in vitro. Furthermore, when injected into athymic nude mice, AS-VEGF189-expressing cells exhibited an 80{\%} decrease in tumor growth compared with control cells. These results support the hypothesis that VEGF promotes pancreatic cancer growth in vivo and suggest that anti-VEGF therapy may be useful in the treatment of this disease.",
keywords = "Angiogensis, Anti-sense RNA, Pancreatic cancer, Tumorigenicity, VEGF",
author = "Jianying Luo and Ping Guo and Kei Matsuda and Nhan Truong and Annie Lee and Carlene Chun and Cheng, {Shi Yuan} and Murray Korc",
year = "2001",
month = "5",
day = "1",
doi = "10.1002/ijc.1202",
language = "English (US)",
volume = "92",
pages = "361--369",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

AU - Luo, Jianying

AU - Guo, Ping

AU - Matsuda, Kei

AU - Truong, Nhan

AU - Lee, Annie

AU - Chun, Carlene

AU - Cheng, Shi Yuan

AU - Korc, Murray

PY - 2001/5/1

Y1 - 2001/5/1

N2 - Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulator that acts by binding to high-affinity transmembrane receptors. Although both VEGF and its receptors are overexpressed in human pancreatic ductal adenocarcinoma (PDAC), this malignancy is not generally considered to be highly vascular. It is not known, therefore, whether the abundance of VEGF in PDAC is biologically relevant. To address this issue, we measured the angiogenic effects of pancreatic cancer cell-derived VEGF in an in vitro endothelial cell proliferation assay and characterized the consequences of suppressing VEGF expression on pancreatic tumor growth in an athymic nude mouse model. We found that human pancreatic cancer cell lines secrete large quantities of biologically active VEGF into conditioned medium (CM). Stable transfection of an anti-sense VEGF189 (AS-VEGF189) expression construct into PANC-1 pancreatic cancer cells resulted in decreased VEGF expression and secretion, a decreased capacity of the resultant CM to enhance endothelial cell proliferation and a significant attenuation of tumor cell proliferation in vitro. Furthermore, when injected into athymic nude mice, AS-VEGF189-expressing cells exhibited an 80% decrease in tumor growth compared with control cells. These results support the hypothesis that VEGF promotes pancreatic cancer growth in vivo and suggest that anti-VEGF therapy may be useful in the treatment of this disease.

AB - Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulator that acts by binding to high-affinity transmembrane receptors. Although both VEGF and its receptors are overexpressed in human pancreatic ductal adenocarcinoma (PDAC), this malignancy is not generally considered to be highly vascular. It is not known, therefore, whether the abundance of VEGF in PDAC is biologically relevant. To address this issue, we measured the angiogenic effects of pancreatic cancer cell-derived VEGF in an in vitro endothelial cell proliferation assay and characterized the consequences of suppressing VEGF expression on pancreatic tumor growth in an athymic nude mouse model. We found that human pancreatic cancer cell lines secrete large quantities of biologically active VEGF into conditioned medium (CM). Stable transfection of an anti-sense VEGF189 (AS-VEGF189) expression construct into PANC-1 pancreatic cancer cells resulted in decreased VEGF expression and secretion, a decreased capacity of the resultant CM to enhance endothelial cell proliferation and a significant attenuation of tumor cell proliferation in vitro. Furthermore, when injected into athymic nude mice, AS-VEGF189-expressing cells exhibited an 80% decrease in tumor growth compared with control cells. These results support the hypothesis that VEGF promotes pancreatic cancer growth in vivo and suggest that anti-VEGF therapy may be useful in the treatment of this disease.

KW - Angiogensis

KW - Anti-sense RNA

KW - Pancreatic cancer

KW - Tumorigenicity

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0035342593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035342593&partnerID=8YFLogxK

U2 - 10.1002/ijc.1202

DO - 10.1002/ijc.1202

M3 - Article

C2 - 11291072

AN - SCOPUS:0035342593

VL - 92

SP - 361

EP - 369

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -